2.68
price down icon5.96%   -0.17
 
loading
Schlusskurs vom Vortag:
$2.85
Offen:
$2.82
24-Stunden-Volumen:
201.00K
Relative Volume:
2.66
Marktkapitalisierung:
$9.22M
Einnahmen:
$468.00K
Nettoeinkommen (Verlust:
$-10.34M
KGV:
-0.3801
EPS:
-7.05
Netto-Cashflow:
$-8.94M
1W Leistung:
+36.04%
1M Leistung:
+18.06%
6M Leistung:
+12.13%
1J Leistung:
-52.36%
1-Tages-Spanne:
Value
$2.55
$3.17
1-Wochen-Bereich:
Value
$2.23
$3.20
52-Wochen-Spanne:
Value
$1.625
$6.15

Biocardia Inc Stock (BCDA) Company Profile

Name
Firmenname
Biocardia Inc
Name
Telefon
650-226-0123
Name
Adresse
320 SOQUEL WAY, SUNNYVALE, CA
Name
Mitarbeiter
17
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
BCDA's Discussions on Twitter

Vergleichen Sie BCDA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
0.41 0 0 0 0 0.00
 icon
GOODO
Gladstone Commercial Corporation
20.23 372.90M 0 0 0 0.00
 icon
PSNYW
Polestar Automotive Holding Uk
0.1601 355.59M 2.07B -1.42B -1.37B -0.6765
 icon
MOBBW
Mobilicom Limited Warrants
0.2199 318.40M 0 0 0 0.00
 icon
JUNE
Dhandho Junoon Etf
11.50 211.65M 0 0 0 0.00
 icon
SHMD
Schmid Group N V
4.00 156.75M 0 0 0 0.00

Biocardia Inc Stock (BCDA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-04-16 Herabstufung Dawson James Buy → Neutral

Biocardia Inc Aktie (BCDA) Neueste Nachrichten

pulisher
May 02, 2025

First subject enrolled in BioCardia’s Phase III heart failure therapy trial - Yahoo

May 02, 2025
pulisher
May 02, 2025

Form 8-KCurrent report - ADVFN

May 02, 2025
pulisher
May 01, 2025

BioCardia Advances Cardiac Cell Therapy With Start Of Phase 3 CardiAMP HF II Trial - Nasdaq

May 01, 2025
pulisher
May 01, 2025

BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Tri - GuruFocus

May 01, 2025
pulisher
May 01, 2025

BioCardia Enrolls First Patient in Phase III Trial - TipRanks

May 01, 2025
pulisher
May 01, 2025

BioCardia's Revolutionary Cell Therapy Enters Final Testing Phase for Heart Failure TreatmentKey Trial Details - Stock Titan

May 01, 2025
pulisher
May 01, 2025

BioCardia (BCDA) Gains Attention Amid Surge in Search Activity | - GuruFocus

May 01, 2025
pulisher
Apr 25, 2025

Biocardia CFO David McClung buys $24,999 in company stock - Investing.com Australia

Apr 25, 2025
pulisher
Apr 25, 2025

Biocardia CFO David McClung buys $24,999 in company stock By Investing.com - Investing.com UK

Apr 25, 2025
pulisher
Apr 25, 2025

BioCardia Executives Increase Their Stakes in the Company - TradingView

Apr 25, 2025
pulisher
Apr 22, 2025

Biocardia CEO Peter Altman acquires $1,488 in stock - MSN

Apr 22, 2025
pulisher
Apr 21, 2025

Beating Heart Patch Market Detailed In New Research Report 2025 | - openPR.com

Apr 21, 2025
pulisher
Apr 20, 2025

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - ADVFN

Apr 20, 2025
pulisher
Apr 18, 2025

Biocardia CEO Peter Altman buys $214 in company stock By Investing.com - Investing.com South Africa

Apr 18, 2025
pulisher
Apr 17, 2025

Biocardia CEO Peter Altman buys $214 in company stock - Investing.com Australia

Apr 17, 2025
pulisher
Apr 16, 2025

DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure - Yahoo

Apr 16, 2025
pulisher
Apr 15, 2025

BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

BioCardia (BCDA) Receives Positive DSMB Recommendation for Cardi - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical Trial - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

BioCardia’s CardiALLO Trial Advances After Safety Review - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial - The Manila Times

Apr 15, 2025
pulisher
Apr 15, 2025

Major Safety Milestone: Revolutionary Heart Failure Cell Therapy Advances to Next Phase - Stock Titan

Apr 15, 2025
pulisher
Apr 14, 2025

Biocardia CEO Altman purchases shares worth $1,206 - Investing.com Australia

Apr 14, 2025
pulisher
Apr 14, 2025

Biocardia CEO Altman purchases shares worth $1,206 By Investing.com - Investing.com India

Apr 14, 2025
pulisher
Apr 14, 2025

Emory begins enrolment for BioCardia’s trial of ischemic heart failure therapy - Yahoo Finance

Apr 14, 2025
pulisher
Apr 12, 2025

BioCardia (BCDA) Advances Phase III CardiAMP HF II Trial with Em - GuruFocus

Apr 12, 2025
pulisher
Apr 12, 2025

BioCardia Initiates Patient Enrollment at Emory University Schoo - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

Emory University joins phase III heart failure trial By Investing.com - Investing.com South Africa

Apr 11, 2025
pulisher
Apr 11, 2025

BioCardia Says Emory University Enrolling Heart Patients for CardiAMP HF II Trial - marketscreener.com

Apr 11, 2025
pulisher
Apr 11, 2025

Emory University joins phase III heart failure trial - Investing.com Australia

Apr 11, 2025
pulisher
Apr 11, 2025

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study - The Manila Times

Apr 11, 2025
pulisher
Apr 11, 2025

Biocardia Initiates Patient Enrollment At Emory University School Of Medicine - MarketScreener

Apr 11, 2025
pulisher
Apr 08, 2025

BioCardia CEO Peter Altman purchases $980 in company stock By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

BioCardia CEO Peter Altman purchases $980 in company stock - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

BioCardia completes enrollment for heart therapy trial - MSN

Apr 08, 2025
pulisher
Apr 07, 2025

Biocardia CEO Peter Altman acquires $1,632 in company shares By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Biocardia CEO Peter Altman acquires $1,632 in company shares - Investing.com Australia

Apr 07, 2025
pulisher
Apr 05, 2025

Biocardia CEO Peter Altman buys $2,435 in company stock By Investing.com - Investing.com South Africa

Apr 05, 2025
pulisher
Apr 04, 2025

Biocardia CEO Peter Altman acquires $2,688 in common stock By Investing.com - Investing.com Australia

Apr 04, 2025
pulisher
Apr 04, 2025

Biocardia CEO Peter Altman buys $2,435 in company stock - Investing.com Australia

Apr 04, 2025

Finanzdaten der Biocardia Inc-Aktie (BCDA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Biocardia Inc-Aktie (BCDA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
McClung David
Chief Financial Officer
Apr 23 '25
Buy
1.91
13,123
24,999
43,131
Facteau Bill
Director
Apr 23 '25
Buy
1.91
13,123
24,999
13,123
Blank Andrew Scott
Director
Apr 23 '25
Buy
1.91
131,233
249,999
265,957
STERTZER SIMON H
Director
Apr 23 '25
Buy
1.91
104,986
199,998
120,365
Altman Peter
President and CEO
Apr 23 '25
Buy
1.91
26,246
49,999
138,966
Altman Peter
President and CEO
Apr 15 '25
Buy
2.14
100
214
112,720
Altman Peter
President and CEO
Apr 11 '25
Buy
2.03
300
609
112,620
Altman Peter
President and CEO
Apr 10 '25
Buy
1.99
300
597
112,320
Altman Peter
President and CEO
Apr 07 '25
Buy
1.96
500
980
112,020
Altman Peter
President and CEO
Apr 04 '25
Buy
2.04
800
1,632
111,520
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
Kapitalisierung:     |  Volumen (24h):